Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California

Pharmacogenetics

Volumn 11, Issue 6, 2001, Pages 489-499

  Yvonne Wan, Y J ^a   Poland, R E ^a   Han, G ^a   Konishi, T ^a   Zheng, Y P ^a   Berman, N ^a   Lin, K M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

African American; CYP2D6; Dextromethorphan; Polymorphism

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN;

ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENZYME ACTIVITY; GENOTYPE; HUMAN; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; ALLELES; CALIFORNIA; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE DUPLICATION; GENE FREQUENCY; HUMANS; MALE; POLYMORPHISM, GENETIC; SEX FACTORS;

EID: 0034891594     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200108000-00004     Document Type: Article

References (42)

1. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients
2. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4
3. High frequency of CYP2D6 poor and 'intermediate' metabolizers in black populations: A review and preliminary data
4. Caucasian genes in American blacks New data
5. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high performance liquid chromatography with application to their disposition in man
6. Effective amplification of long targets from cloned inserts and human genomic DNA
7. Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness
8. Polymorphic cytochromes P450 and drugs used in psychiatry
9. Nomenclature for human CYP2D6 alleles
10. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians
11. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans
12. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism
13. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data
14. Basic pharmacokinetic principles and their application to psychotropic drugs
15. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population
16. The human CYP2D locus associated with a common genetic defect in drug oxidation: A G1934→A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site
17. Eur J, Dextromethorphan O-demethylation polymorphism in an African-American population
18. Pharmacogenetics in the new patterns of healthcare delivery
19. 'It's the genes, stupid': Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism
20. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies
21. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles
22. Psychopharmacotherapy in the context of culture and ethnicity
23. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes
24. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution
25. Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy black American adult subjects
26. Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine
27. Genetic polymorphism of drug metabolising enzymes in African populations: Implications for the use of neuroleptics and antidepressants
28. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity
29. Pharmacogenetics: The slow, the rapid, and the ultrarapid
30. Antidepressants and drug-metabolizing enzymes-expert group report
31. Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?
32. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): Evidence for two major allozymes in extensive metabolisers
33. Estimating African American admixture proportions by use of population-specific alleles
34. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6
35. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects
36. Polymorphic dextromethorphan metabolism: Cosegregation of oxidative O-demethylation with debrisoquine hydroxylation
37. The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse
38. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology
39. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): Potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6
40. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RELP and DNA sequence of CYP2D6